Galderma will present data from its Injectable Aesthetics portfolio at the TOXINS 2026 International Conference, held in Madrid, Spain from January 14-17.
First author | Abstract number & title | Presentation type |
E. Nicodème | Similar and Limited In Vivo Diffusion for relaBoNT-A and onaBoNT-A – Abstract 0103 | Poster |
G. Ablon | RelaBoNT-A Treatment of Glabellar Lines and Lateral Canthal Lines of Different Baseline Severity: Subgroup Analyses of Pooled Phase III Study Data – Abstract 0080 | Poster |
S.E. Cox | RelabotulinumtoxinA Treatment Improved Moderate to Severe Glabellar Lines and Lateral Canthal Lines Regardless of Baseline Toxin Naivety: Subgroup Analyses of Pooled Phase 3 Study Data – Abstract 0079 | Poster |
J. Schlessinger | High Subject Satisfaction With AbobotulinumtoxinA Treatment of Glabellar Lines Post-Marketing Across the Globe – Abstract 0077 | Poster |
J. Huang | Subject and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatments of Glabellar Lines in Chinese Subjects: Results From a Real-World Study – Abstract 0075 | Poster |
The company will also host a Relfydess® Masterclass in which expert speakers will discuss clinical data, real-world treatment experience, and the science behind Relfydess’ PEARL™ Technology
Speakers | Event type & title | Details |
J. Czuwara & B. Blessman-Gurk
| Relfydess Masterclass | Thursday, January 15; 15:50 – 16:20 CET; Educational Theatre |
All authors are paid consultants of Galderma.